Neximmune Inc - ESG Rating & Company Profile powered by AI
If you work at Neximmune Inc and you wish to licence your Sustainability rating, please get in touch. Comprehensive Sustainability assessment of Neximmune Inc can be accessed by signing in. The analysis of Neximmune Inc was prepared by All Street Sevva using leading NLP.
Neximmune Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 1.2; made up of an environmental score of 0.0, social score of 1.3 and governance score of 2.3.
1.2
Low ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Novartis AG | 9.2 | High |
| 2 | Daiichi Sankyo Co Ltd | 8.9 | High |
| ... | ... | ... | |
| 2454 | Weed Inc | 1.3 | Low |
| 2454 | Zyla Life Sciences | 1.3 | Low |
| 2477 | Neximmune Inc | 1.2 | Low |
| 2477 | Biostem Technologies Inc | 1.2 | Low |
| 2477 | Biotoxtech Co Ltd | 1.2 | Low |
| 2749 | Xynomic Pharmaceuticals Holdings Inc | 0.0 | Low |
| 2749 | Zyden Gentec Ltd | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Neximmune Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Neximmune Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes Neximmune Inc report the average age of the workforce?
Sign up for free to unlockDoes Neximmune Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Neximmune Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes Neximmune Inc disclose cybersecurity risks?
Sign up for free to unlockDoes Neximmune Inc offer flexible work?
Sign up for free to unlockDoes Neximmune Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Neximmune Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Neximmune Inc conduct supply chain audits?
Sign up for free to unlockDoes Neximmune Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Neximmune Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes Neximmune Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes Neximmune Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Neximmune Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Neximmune Inc disclose water use targets?
Sign up for free to unlockDoes Neximmune Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid Neximmune Inc have a product recall in the last two years?
Sign up for free to unlockDoes Neximmune Inc disclose incidents of discrimination?
Sign up for free to unlockDoes Neximmune Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Neximmune Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Neximmune Inc disclose parental leave metrics?
Sign up for free to unlockDoes Neximmune Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Neximmune Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Neximmune Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes Neximmune Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Neximmune Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Neximmune Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Neximmune Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes Neximmune Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Neximmune Inc disclose its waste policy?
Sign up for free to unlockDoes Neximmune Inc report according to TCFD requirements?
Sign up for free to unlockDoes Neximmune Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Neximmune Inc disclose energy use targets?
Sign up for free to unlockDoes Neximmune Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Neximmune Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Neximmune Inc
These potential risks are based on the size, segment and geographies of the company.
NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a candidate targeted against HPV-associated malignancies, which is in preclinical stage. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.